Quercetin reduces Streptococcus suis virulence by inhibiting suilysin activity and inflammation

https://doi.org/10.1016/j.intimp.2019.01.017Get rights and content

Highlights

  • We found that the natural compound quercetin can directly inhibit the pore-forming activity of SLY without affecting bacterial growth and SLY secretion.

  • Quercetin can reduce the S. suis-mediated inflammatory response by suppressing the expression of the intracellular signaling pathways p38MAPK, ERK1/2 and NF-κB.

  • Treatmnt with quercetin alleviated S. suis virulence both in vitro and in vivo.

  • Our results suggested that quercetin may represent a candidate for S. suis infection with novel therapeutics strategy.

Abstract

Streptococcus suis, a globally distributed bacterial pathogen, is an important zoonotic agent for humans and animals that can lead to multiple deaths and cause major economic losses. Suilysin (SLY), secreted by most pathogenic S. suis strains, is a cytotoxic toxin that belongs to the cholesterol-dependent cytolysin family; this toxin plays a key role in a mouse meningitis model, suggesting that effective interference with the biological activity of SLY may be a potential treatment for S. suis infection. In addition, the inflammatory response induced by S. suis is an important manifestation in infections and is associated with multiple fatal diseases. In this study, we found that the natural compound quercetin can directly inhibit the pore-forming activity of SLY without affecting bacterial growth and SLY secretion at the concentrations tested in our assay. In addition, quercetin treatment significantly alleviated cytotoxicity caused by S. suis infection and effectively reduced the release of the pro-inflammatory cytokines IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α) stimulated by bacteria. Significantly decreased mortality was observed for the S. suis-infected mice that received quercetin. Our results suggested that quercetin may represent a promising therapeutic candidate for S. suis infection by targeting SLY and the subsequent inflammation. The present study provides a new strategy and leading compound for S. suis infection.

Introduction

Streptococcus suis (S. suis), one of the most important pathogens in the swine industry, is a gram-positive bacterium commonly found worldwide that can cause major economic losses and several fatal infections, including streptococcal toxic shock syndrome (STSS), meningitis and arthritis [[1], [2], [3]]. In the United States alone, this bacterium has resulted in the loss of hundreds of millions of dollars per year [4]. S. suis is considered an emerging and serious threat to public safety, as it is an opportunistic zoonotic pathogen [3]. To date, more than 30 serotypes of S. suis have been identified based on the specificity of the capsule antigens [5], and serotype 2 is the most frequently isolated serotype from clinically infected pigs worldwide [6,7];most meningitis cases are caused by S. suis type 2 (SS2) [5]. This bacterium poses a major hazard to pig producers and pork processors who have close contact with pigs and pork products or consumers who eat undercooked pork [5,8]. Approximately 1650 cases of human S. suis infections were reported worldwide before 2014 [9]. In the southeast Asian countries Vietnam and Thailand, S. suis infection is one of the leading causes of bacterial meningitis in adults [10,11]. In 1998 and 2005, two severe outbreaks of S. suis occurred in China. Hundreds of people were infected, and dozens of deaths occurred in a short period of time, which caused a major public health crisis, incalculable economic losses and serious consequences [12,13]. S. suis infections have caused serious public health issues, and effective treatment methods and strategies are urgently needed.

More than half of Chinese patients infected by SS2 in the aforementioned outbreak in 2005 had an unusual clinical manifestation of STSS, including disseminated intravascular coagulation, which was associated with platelet-bacterium interactions, and these patients showed increased mortality [[13], [14], [15]]. Suilysin (SLY), a secreted toxin of most virulent S. suis strains, was reported as the sole stimulatory factor for platelet activation and aggregation in the infections caused by S. suis. Moreover, the SLY-negative SS2 strain 1330 could not induce platelet aggregation [16], suggesting SLY may play a crucial role in DIC of STSS induced by SS2. SLY is an important exocrine toxin of SS2, a member of the cholesterol-dependent cytolysin (CDC) family, which can create pores in cholesterol-containing membranes and then lead to cell lysis [17,18]. The role and mechanism of SLY in human infections with SS2 are still unclear; however, the worldwide clinical case records show that SLY-positive strains led to more severe symptoms in China and southeast Asia than SLY-negative strains in North America [10,19,20]. In addition, Takeuchi et al. found that S. suis ST1, a strain producing high levels of SLY, caused meningitis more often than strains that produced low levels of SLY or no SLY [21]. In addition, the SS2 strain 05ZYH33 with increased SLY production showed hypervirulence in vivo and in vitro compared to S. suis 1940, a strain with lower levels of SLY production, which had a higher ability to penetrate the epithelium and survive in the bloodstream [22]. Moreover, SLY could also stimulate the release of heparin binding protein, induce inflammatory responses and increase the vascular permeability in mice [23]. Furthermore, SLY played an important role in a mouse model of SS2 meningitis. The mice infected with high levels of the SLY-producing strain had survival rates of less than 10%; however, in another group of mice used as a control, which was infected with a low level of the SLY strain, or a sly knockout strain, only a few deaths were observed, and mortality decreased significantly. Compared with the group infected with the strain producing high levels of SLY, the control group showed significantly reduced colony colonization and inflammation in the brain. These results further demonstrated that SLY was a crucial factor contributing toSS2 meningitis [21]. Thus, SS2 requires a series of virulence factors to successfully infect and cause host disease; SLY plays a crucial role in this process and may be related to STSS and meningitis. Therefore, SLY could be a potential new target for the treatment of SS2 infection.

S. suis infection can trigger a series of severe inflammatory reactions, especially arthritis and meningitis [5]. An excessive inflammatory response is a manifestation of STSS induced by SS2 [24]. Several studies have suggested that the increasing permeability through the blood-brain barrier during SS2 infection was stimulated by inflammatory reactions or mediators that occurred during adhesion and infection [25]. In addition, SS2 could stimulate monocytes/macrophages and produce pro-inflammatory cytokines, including IL-1β, IL-6, TNF-α and monocyte chemotactic protein-1 (MCP-1) [26,27]. In addition, SS2 infection results in recognition of toll-like receptor 2 (TLR 2) and activation of members of the mitogen-activated protein kinase (MAPK) pathway, including c-Jun N-terminal kinase (JNK) and p38MAPK extracellular-signal-regulated kinase (ERK), which are closely related to the inflammatory response and can also regulate cell differentiation, proliferation and death [28,29]. A series of inflammatory reactions induced by SS2 are also an important part of the pathogenic process. Therefore, attenuating the inflammatory response of SS2 may be an important strategy for the treatment of SS2 infection.

Antimicrobial therapy is currently the main method for clinical treatment of SS2 infection [30], but bacterial resistance is becoming increasingly serious, especially given that the rate of development of new antibiotics is much lower than the emergence of bacterial resistance [31]. To effectively improve or eliminate the current unfavorable situation in the fight against S. suis infection, new anti-infective strategies and agents are urgently needed. In recent years, anti-virulence strategies have been recognized as promising and effective approaches to fight the rapid development of drug resistance [32]. Targeting virulence factors does not affect the normal growth of bacteria [33] and does not put a strong survival selection pressure on bacteria, which may delay the emergence of drug resistance. However, treatment with anti-virulence agents could significantly reduce the pathogenicity of pathogens [32,33]. At present, anti-virulence strategies using specific antibodies against α-hemolysin can significantly inhibit the virulence of S. aureus in vitro and in vivo [34].

Quercetin is a natural flavonoid that can be extracted from a variety of plants and fruits and has various pharmacological and biological effects, including antiviral, antioxidation, anticancer and anti-inflammatory effects [[35], [36], [37], [38]]. Recent studies have found that quercetin could inhibit obesity and obesity-induced inflammation in cells and mice, which could also inhibit angiogenesis in nasopharyngeal carcinoma [39,40]. In addition, quercetin induced the differentiation of bone marrow mesenchymal stem cells [41]. However, the effect of quercetin in infections caused by SS2 and the interaction with SLY have not been reported thus far. In this study, we demonstrate that the natural bioflavonoid compound quercetin could inhibit the activity of SLY by preventing SLY oligomerization and significantly reduce the inflammatory response in SS2 infected cells and the mortality in infected mice. Thus, our results suggested quercetin may be a promising therapeutic candidate to treat SS2 infections.

Section snippets

Bacterial strain and regents

The strain used in this study was the highly virulent SS2 ZY05719, which was isolated from pigs and kindly provided by Professor Hongjie Fan from Nanjing Agricultural University (Nanjing, China). Cell culture medium (Dulbecco's modified Eagle's medium, DMEM) was purchased from Invitrogen. Fetal bovine serum (FBS) was purchased from Biological Industries (BI). The bacterial medium Todd-Hewitt broth (THB) was obtained from Qingdao Hope Bio-Technology (Qingdao, China). Dimethyl sulfoxide (DMSO)

Quercetin inhibits SLY pore-forming activity without interfering with SS2 viability

The MIC of the natural flavonoid quercetin (Fig. 1A) on SS2 was more than 1024 μg/mL; additionally, no significant difference was observed for the growth of SS2 in the presence of various concentrations of quercetin (Fig. 1B). These data suggested that quercetin had no anti-SS2 activity and did not affect the viability of SS2. After SS2 was co-cultured with quercetin, the hemolytic activity of SS2 culture supernatants was evaluated by hemolysis assays. As shown in Fig. 1C, the bacterial culture

Discussion

Similarly, anti-virulence strategies can also be used for SS2infections. Among the various virulence factors, SLY plays an important role in SS2 pathogenicity, as deletion of SLY can significantly reduce the pathogenicity of SS2 in mice [21]. In addition, SLY can increase the vascular permeability of mice, which is related to STSS [23]. Strains producing high-level SLY, but not strains with weak SLY secretion, are more likely to cause meningitis in humans [21]. In addition, SLY could facilitate

Conflicts of interest

None of the authors have a financial interest in any of the products, devices, or Materials mentioned in this manuscript. The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the National Key Technology R&D Program (No. 2016YFD05013), the National Natural Science Foundation of China (grant 31602109) and the Jilin Scientific and Technological Development Program under Grant 20190103147JH.

References (45)

  • J.J. Staats et al.

    Streptococcus suis: past and present

    Vet. Res. Commun.

    (1997)
  • M. Gottschalk et al.

    Streptococcus suis: a new emerging or an old neglected zoonotic pathogen?

    Future Microbiol

    (2010)
  • M.C. Heidt et al.

    Human infective endocarditis caused by Streptococcus suis serotype 2

    J. Clin. Microbiol.

    (2005)
  • G. Goyette-Desjardins et al.

    Streptococcus suis, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing

    Emerg. Microbes Infect.

    (2014)
  • M. Gottschalk et al.

    Dilemma of the virulence of Streptococcus suis strains

    J. Clin. Microbiol.

    (1999)
  • S.J. King et al.

    Distribution and genetic diversity of suilysin in Streptococcus suis isolated from different diseases of pigs and characterization of the genetic basis of suilysin absence

    Infect. Immun.

    (2001)
  • T. Tenenbaum et al.

    Biological activities of suilysin: role in Streptococcus suis pathogenesis

    Future Microbiol

    (2016)
  • H.F. Wertheim et al.

    Streptococcus suis, an important cause of adult bacterial meningitis in northern Vietnam

    PLoS One

    (2009)
  • N. Fittipaldi et al.

    Virulence factors involved in the pathogenesis of the infection caused by the swine pathogen and zoonotic agent Streptococcus suis

    Future Microbiol

    (2012)
  • W.Z. Yang et al.

    An outbreak of human Streptococcus suis serotype 2 infections presenting with toxic shock syndrome in Sichuan, China

    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

    (2006)
  • H. Yu et al.

    Human Streptococcus suis outbreak, Sichuan, China

    Emerg. Infect. Dis.

    (2006)
  • S. Sriskandan et al.

    Invasive disease and toxic shock due to zoonotic Streptococcus suis: An emerging infection in the East?

    PLoS Med.

    (2006)
  • Cited by (25)

    • The controlled design of electrospun PCL/silk/quercetin fibrous tubular scaffold using a modified wound coil collector and L-shaped ground design for neural repair

      2020, Materials Science and Engineering C
      Citation Excerpt :

      Also, the treatments of growth factors, such as NGF, are limited by their high cost and unpredictable effects. As an alternative to traditional clinical applications using growth factors for neural repair, numerous studies have revealed that quercetin increases neuron survival, enhances the inherent regenerative capacity, and reduces inflammation [14–18]. Quercetin, found in many vegetables, aromatic herbs, or fruits, is a ubiquitous flavonoid compound from the polyphenolic group as shown in Fig. 1.

    • Complement C3aR/C5aR-binding protein Suilysin of Streptococcus suis contributes to monocyte chemotaxis

      2020, Veterinary Microbiology
      Citation Excerpt :

      Additionaly, we are trying to obtain a double or more gene deleted mutants of other CBPs screed in this study to test ther roles and if any synergistic effect of Suilysin and other CBPs existed although this is not an easy thing. Suilysin contributed to pathogenesis of S. suis infection (Takeuchi et al., 2014), complement-mediated killing (Lecours et al., 2011) and was essential for the full virulence of the epidemic strain (Li et al., 2017, 2019). Suilysin has been demonstrated to play an important role in the invasive S. suis infection (Lv et al., 2014), the high level of inflammasome activation by S. suis (Lin et al., 2019), being the main stimulus for TNF-α production independently of its membrane perforation ability (Bi et al., 2015).

    • Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems

      2020, Drug Discovery Today
      Citation Excerpt :

      In one of the studies, quercetin reduced Streptococcus suis-induced inflammation by inhibiting the intracellular motioning pathways p38 mitogen-activated protein kinase (MAPK), nuclear factor kappa beta cell enhancer (NF-κB), and extracellular signal-related kinases (ERK1/2). It also diminished the release of the proinflammatory cytokines IL-1β, IL-6, and TNF-α [15]. Junyuan et al. reported that quercetin inhibited endoplasmic reticulum stress (ERS) and TLR4/MyD88/p38 MAPK pathway activation and decreased IL-1β, IL-6 and TNFα levels, hence protecting against intestinal inflammation [16].

    • Inhibition of Myristic Acid on Suilysin and the Molecular Mechanism

      2023, Science and Technology of Food Industry
    View all citing articles on Scopus
    1

    These authors contributed equally to this article.

    View full text